Literature DB >> 862195

Estimation of o,p'-DDD in plasma by gas-liquid chromatography.

A J Moolenaar, J W Niewint, I T Oei.   

Abstract

A method is described for the estimation of o,p'-DDD in plasma. To 50 microl plasma, 0.2 ml acetone is added. The mixture is extracted with 2 ml n-heptane containing p,p'-DDD as an internal standard. Water is removed by adding desiccated sodium sulfate. The organic phase can be injected into a gas chromatograph equipped with an electron capture detector. The o,p'-DDD content of the sample can be read from a calibration curve. Recovery of o,p'-DDD added to plasma is over 93%. The same procedure can be used for the estimation of o,p'-DDE.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862195     DOI: 10.1016/0009-8981(77)90098-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.

Authors:  Y Touitou; A J Moolenaar; A Bogdan; A Auzéby; J P Luton
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy.

Authors:  H von Slooten; A P van Seters; D Smeenk; A J Moolenaar
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.

Authors:  D O Gebhardt; A J Moolenaar; A P van Seters; E A van der Velde; J A Gevers Leuven
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.

Authors:  A J Moolenaar; H van Slooten; A P van Seters; D Smeenk
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma.

Authors:  H R Haak; C J Cornelisse; J Hermans; L Cobben; G J Fleuren
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

6.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

Authors:  H R Haak; J Hermans; C J van de Velde; E G Lentjes; B M Goslings; G J Fleuren; H M Krans
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

7.  A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry.

Authors:  Motozumi Ando; Masaki Hirabatake; Hisateru Yasui; Shoji Fukushima; Nobuyuki Sugioka; Tohru Hashida
Journal:  Biomed Chromatogr       Date:  2020-01-28       Impact factor: 1.902

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.